Table 1.

Laboratory parameters and rheumatological indications of the drugs used to treat COVID-19.

Drugs	Rheumatological Indications	Laboratory Parameters	Contraindications
Chloroquine and hydroxychloroquine	RA, SLE, SS	Cytopenia, long QT	Maculopathy, retinal changes, hypersensitivity, G6PD deficiency
IVIG	Off-label	Decrease in Hb levels, positive Coombs test, increase in blood lactate dehydrogenase and liver enzyme levels	Hypersensitivity, type I or II hyperprolinemia
Anti-TNF drugs	RA, JIA, SpA, PsA, BD	Cytopenia, increase in ALT levels, prolongation of activated partial thromboplastin time, auto-antibody test positivity (including double stranded DNA antibodies),	Hypersensitivity, active tuberculosis or other severe infections, NYHA III IV
Anti- IL 6 drugs	RA, JIA, cytokine release syndrome, GCA	Increase in liver enzyme levels, decrease in neutrophil and platelet counts	Hypersensitivity, active severe infections
Anti- IL 1 drugs	RA, CAPS	Decrease in neutrophil and platelets counts, increase in eosinophil differential percentage	Hypersensitivity
Baricitinib	RA	Decrease in neutrophil and lymphocyte counts, decrease in Hb levels, alterations in lipid parameters, increase in liver enzyme and creatine phosphokinase levels	Hypersensitivity, pregnancy
Colchicine	Gout, Familial Mediterranean Fever, BD	Decrease in neutrophil and lymphocytes, hepatic/renal function alteration	Hypersensitivity

RA: rheumatoid arthritis; JIA: juvenile rheumatoid arthritis; SpA: spondyloarthritis; PsA: psoriatic arthritis; SLE: systemic lupus erythematosus; SS: Sjögren syndrome; CAPS: cryopyrin-associated periodic syndrome; G6PD: glucose-6-phosphate dehydrogenase; BD: Behçet disease; GCA: giant cell arteritis.